ChatGPT for doctors
OpenEvidence, a startup often compared by healthcare professionals to ChatGPT, a smart chatbot for medicine, is set to announce a new investment round worth an estimated €172 million, according to The New York Times. This comes just three months after the company raised $210 million at a valuation of $3.5 billion. This is indeed a sign of the overwhelming interest of investors in purpose-built AI solutions.
The platform is trained on reputable medical sources such as JAMA and the New England Journal of Medicine, and provides quick access to verified medical information. The tool is free for verified doctors and nurses, as it is supported by advertising.
OpenEvidence has grown rapidly since its founding in 2022. The number of monthly clinical consultations has nearly doubled to 15 million since July. The new investment round is led by Google Ventures, with participation from Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond and Craft.
OpenEvidence thus solidifies its position as one of the leading AI platforms in healthcare, effectively combining accuracy, speed, and accessibility for healthcare professionals.

























